Fundamental Analysis of Protagonist Therapeutics Inc - Growth / Value Index


PTGX - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 12.50
   Price to Book Ratio of 2609.16 suggesting that it is very expensive
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 5039.25 -11374.21 -104858.61 %
Price to Book 2389.32 4746.07 74022.63 % 3.19
Price to Sales 2593.76 26631.57 51176.63 %
Enterprise Value to EBITDA Multiple 9.53 -11648.16 -115308.83 %


PTGX - Profitability Highlights

Profitability Analysis

   Tsr Profitability Index - Good Score of 73.12
   During the past twelve months, the company has given a strong Return On Equity of 47.41%
   During the past twelve months, the company has given a strong Return On Asset of 43.17%
   During the past twelve months, the company has given a strong Net Margin of 51.47%
   All key Trailing Twelve Months Margin growing by 15 %
   Piotroski F Score - Stable Value of 4.0
   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   Steady Growth in EPS for last four quarters
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 47.41 -41.73 29.38 % 37.00
Return On Asset 43.17 -39.25 23.62 % 32.95
Net Profit Margin 51.47 -234.14 51.15 % 81.32
Operating Profit Margin 47.21 -255.36 48.33 % 80.92
EBITDA Margin 48.83 -228.61 51.22 % 80.92


Highlights
Market Cap1651.06 M
Enterprise Value1465.47 M
Price/Book TTM2389.32
Outstanding Share58652.10 K
Float/ Outstanding Share73.37%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No1031.00
Peter Lynch Ratio0
Piotroski F Score4.00
Altman Z Score44.15
Sloan Ratio-0.060
Peter Lynch Fair Value0


PTGX - Growth Highlights

Growth Analysis

   STRONG JUMP IN NET SALE : YoY growth
   Quarterly sales in last 5 years is trending up
   Steady increase in Total Assets for last 3 Years
   Tsr Growth Index - Poor Score of 25.38
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 314953 K 125.73 % 324.92 %
Gross Profit 313305 K 125.73 % 324.92 %
EBITDA 153796 K 10.11 % 632.45 %
Net Profit 162110 K 10.28 % 658.51 %
EPS 0.0056 99.90 % NA


PTGX - Stability Highlights

Stability Analysis

   Altman Z Score of 48.43 suggests good Stability
   Paid More Than 50% of Debt, Heading towards debt free
   Debt to equity ratio has decreased and is lowest in last five years
   Cash ratio of 16.06
   Company financial liquidity has improved
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of 0
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.0034 -70.95 % 0.0008
Cash Ratio 16.06 110.94 %
Quick Ratio 17.20 120.53 % 15.72
Shareholders Equity 94.06 8.16 %
Debt to EBITDA -0.0083 58.80 %


Historical Valuation Ratios of Protagonist Therapeutics Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Protagonist Therapeutics Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Protagonist Therapeutics Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Protagonist Therapeutics Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)